This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Mitofusin 2 (MFN2) gene encodes an outer mitochondrial membrane protein which plays a central role in mitochondrial fusion.1 Mutations in the MFN2 gene have recently been reported to cause up to 33% of axonal peripheral neuropathies which in some cases involved the CNS.2,3 Since an initial study, which linked MFN2 mutations with Charcot-Marie-Tooth disease type 2A (CMT2A),4 MFN2 mutations have also been found in CMT with optic atrophy (CMT6).5 MFN2 prevents cell death following DNA damage and K+ deprivation induced apoptosis beyond its role of mitochondrial fusion.6 Furthermore, it has been reported that mitochondrial fusion defect is an early event of ischemic stroke.7
We report a case with early-onset stroke putatively caused by a novel MFN2 mutation. To our knowledge, no previous report has been published concerning CNS involvement without peripheral neuropathy caused by MFN2 mutations.
Case reports.
Patient 1.
The proband was admitted at 12 years of age because of sudden development of vomiting and gait ataxia. She did not show any delay in developmental milestones. In tandem gait, she kept veering to the right side, and showed marked intention tremor. Laboratory examinations disclosed elevated plasma lactate (42.6 mg/dL; normal: 7.4–27.1 mg/dL) and pyruvate levels (0.78 mg/dL; normal: 0.30–0.70 mg/dL). The ratio of lactate/pyruvate was 54.6 (normal: 10–20). In addition, her hemoglobin …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham